Pricing Log in Create free account

Aardvark Therapeutics, Inc. (AARD) vs Rallybio Corporation (RLYB)

Aardvark Therapeutics, Inc. and Rallybio Corporation are both Biotechnology companies. Aardvark Therapeutics, Inc. and Rallybio Corporation are of similar size ($89.1M and $84.5M). Aardvark Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Rallybio Corporation trades at 2.0×. Across the 9 metrics below, Rallybio Corporation leads on 9 and Aardvark Therapeutics, Inc. on 0.

Valuation

Metric AARD RLYB Biotechnology median
P/E n/m 2.02 8.50
P/S n/m 108.13 9.71
P/B 1.10 0.98 2.13
Price to free cash flow n/m 3.48 20.82
EV/EBITDA n/m 0.00 0.64
EV/Sales n/m (0.08) 9.21
Earnings yield (84.92%) 49.50% (33.15%)
Free cash flow yield (84.17%) 28.76% (25.50%)

Profitability

Metric AARD RLYB Biotechnology median
Gross margin — 100.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (66.02%) 64.86% (56.36%)
Return on assets (61.06%) 61.12% (48.04%)
Return on invested capital (4,986.18%) (1,052.03%) 0.00%

Growth

Metric AARD RLYB Biotechnology median
Revenue growth (TTM) — 1.18% 6.02%
EPS growth (last fiscal year) 43.11% 85.06% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric AARD RLYB Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 12.63 27.26 4.72
Net debt to EBITDA 1.72 1.63 0.96

Dividend

Metric AARD RLYB Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric AARD RLYB Biotechnology median
Market cap 84.47m 89.08m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack